Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PRKCA | P17252 | 4/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16504781 | 1.00 | LMNA (0.39) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL9617221 | 1.00 | LMNA (0.39) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL11883705 | 1.00 | LMNA (0.39) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL10957671 | 0.98 | LMNA (0.40) | LMNAPRKCAGAAALDH1A1 | |
| SCHEMBL6682873 | 0.93 | PRKCA (0.35) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL10492039 | 0.93 | PRKCA (0.35) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL10491968 | 0.93 | PRKCA (0.35) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL676710 | 0.93 | PRKCA (0.35) | LMNAPRKCASIRT2THRATHRB | |
| SCHEMBL9414401 | 0.91 | EPHX2 (0.39) | PRKCA | |
| SCHEMBL9848776 | 0.91 | EPHX2 (0.39) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6192194-A | — | — | None | — | — | JP | disclosed |
| US-8888907-B2 | Solid phase change ink compositions comprising oxazolines | XEROX CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-8524259-B2 | Systems and methods for delivery of materials | LANDEC CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-8506694-B2 | Phase separation ink | XEROX CORPORATION (US) | 2013-08-13 | — | — | US | disclosed |
| US-8500260-B2 | Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives | XEROX CORPORATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-8481609-B2 | Phase change inks containing oxazoline compounds and polyterpene resins | XEROX CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8460447-B2 | Substituted oxazoline compounds or substituted oxazoline derivatives | XEROX CORPORATION (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130032057-A1 | SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING OXAZOLINES | XEROX CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035428-A1 | Phase Change Inks Containing Oxazoline Compounds and Polyterpene Resins | XEROX CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120274713-A1 | Phase Separation Ink | XEROX CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20090263346-A1 | Systems and methods for delivery of drugs | LANDEC CORPORATION | 2009-10-22 | — | — | US | disclosed |
| US-20090246155-A1 | Compositions and methods for personal care | LANDEC CORPORATION | 2009-10-01 | — | — | US | disclosed |
| JP-H06192194-A | PRODUCTION OF BRANCHED FATTY ACID AMIDE | KAO CORP | 1994-07-12 | — | — | JP | disclosed |
| US-4507161-A | OXYGEN RELEASING SALT, EMULSIFIERS | ICI AUSTRALIA LIMITED (AU) | 1985-03-26 | — | — | US | disclosed |
| EP-0008507-B1 | DERIVATIVES OF 2-OXAZOLINES AS ANTIOXIDANTS AND COMPOSITIONS THEREOF | UNIROYAL, INC. (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4216040-A | CATIONIC EMULSIFIER HAVING HYDROPHILIC AND LIPOPHILIC PORTIONS; WATER IN OIL EMULSION | IRECO CHEMICALS (US) | 1980-08-05 | — | — | US | disclosed |
| EP-0008507-A1 | Derivatives of 2-oxazolines as antioxidants and compositions thereof | UNIROYAL, INC. (US) | 1980-03-05 | — | — | EP | disclosed |
| US-4112138-A | Manifold carbonless form and process for the production thereof | THE MEAD CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4097619-A | Manifold carbonless form and process for the continuous production thereof | THE MEAD CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-3967015-A | COATING OF THERMOSETTING EPOXY RESIN AND AN OXAZOLINE | COMMERCIAL SOLVENTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263346-A1 | Systems and methods for delivery of drugs | CYCS, CTRC, PPIC | LMNA 1770/4885PRKCA 1007/4885SIRT2 3194/4885 |
| US-20090246155-A1 | Compositions and methods for personal care | PPIC, CYCS, CTRC | LMNA 1158/4885PRKCA 439/4885SIRT2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.